Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

BACKGROUND: Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Schraa, S. J., van Rooijen, K. L., van der Kruijssen, D. E. W., Rubio Alarcón, C., Phallen, J., Sausen, M., Simmons, J., Coupé, V. M. H., van Grevenstein, W. M. U., Elias, S., Verkooijen, H. M., Laclé, M. M., Bosch, L. J. W., van den Broek, D., Meijer, G. A., Velculescu, V. E., Fijneman, R. J. A., Vink, G. R., Koopman, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441668/
https://www.ncbi.nlm.nih.gov/pubmed/32819390
http://dx.doi.org/10.1186/s12885-020-07252-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441668/
https://www.ncbi.nlm.nih.gov/pubmed/32819390
http://dx.doi.org/10.1186/s12885-020-07252-y

Ejemplares similares